What Is Gabapentin?
Gabapentin (brand name: Neurontin) is a prescription medication originally developed as an anticonvulsant for epilepsy. It is structurally related to GABA (gamma-aminobutyric acid), the brain's main inhibitory neurotransmitter, but paradoxically does not bind to GABA receptors. Instead, it binds to the alpha-2-delta subunit of voltage-gated calcium channels in the nervous system, reducing the release of excitatory neurotransmitters.
Gabapentin is the 9th most prescribed drug in the United States, with approximately 46 million prescriptions dispensed annually. Despite its widespread use, it is one of the most controversial drugs in medicine — prescribed for dozens of off-label conditions with varying levels of evidence, and increasingly recognized as having abuse potential.
FDA-Approved Uses
| Indication | Approved Population | Typical Dose |
|---|---|---|
| Partial seizures (adjunct therapy) | Adults and children ≥3 years | 900–3,600 mg/day in 3 divided doses |
| Postherpetic neuralgia (PHN) | Adults | 1,800–3,600 mg/day in 3 divided doses |
| Restless legs syndrome (Horizant ER formulation only) | Adults | 600 mg once daily at 5 PM |
Off-Label Uses (With Evidence Quality)
| Off-Label Use | Evidence Quality | Notes |
|---|---|---|
| Diabetic peripheral neuropathy | Moderate (multiple RCTs) | Effective; FDA-approved pregabalin is an alternative |
| Fibromyalgia | Moderate | Pregabalin is FDA-approved; gabapentin used off-label |
| Alcohol withdrawal | Moderate (growing evidence) | May reduce withdrawal symptoms and cravings |
| Anxiety disorders | Low-Moderate | Not FDA-approved; used when other options fail |
| Chronic low back pain | Low (weak evidence) | 2019 JAMA study found no benefit over placebo for acute sciatica |
| Perioperative pain | Moderate | Part of multimodal analgesia protocols |
| Hot flashes (menopause) | Moderate | Non-hormonal option; FDA-approved Brisdelle (paroxetine) preferred |
| Bipolar disorder | Low (limited evidence) | Not recommended by most guidelines |
| Insomnia | Low-Moderate | Sedating; used off-label but not first-line |
How Gabapentin Works
Despite its name, gabapentin does not bind to GABA receptors. Its primary mechanism is binding to the alpha-2-delta (α2δ) subunit of voltage-gated calcium channels, particularly in the dorsal horn of the spinal cord and in the brain. This binding reduces calcium influx into nerve terminals, decreasing the release of excitatory neurotransmitters (glutamate, norepinephrine, substance P) involved in pain signaling and seizure generation.
The result is reduced neuronal excitability — which explains its efficacy in neuropathic pain (where sensitized pain neurons fire excessively) and in epilepsy (where abnormal electrical discharges propagate through the brain).
Dosing Guide
| Indication | Starting Dose | Titration | Target Dose | Max Dose |
|---|---|---|---|---|
| Epilepsy (adjunct) | 300 mg at bedtime × 1 day | 300 mg TID on day 2, then 300 mg TID on day 3 | 900–1,800 mg/day | 3,600 mg/day |
| Postherpetic neuralgia | 300 mg on day 1, 300 mg BID day 2, 300 mg TID day 3 | Titrate as tolerated | 1,800 mg/day | 3,600 mg/day |
| Neuropathic pain | 100–300 mg at bedtime | Increase by 100–300 mg every 1–3 days | 1,200–2,400 mg/day | 3,600 mg/day |
| Anxiety (off-label) | 100–300 mg TID | Titrate slowly | 900–1,800 mg/day | 2,400 mg/day |
Renal dosing: Gabapentin is renally eliminated and requires significant dose reduction in renal impairment. Patients with eGFR <60 mL/min/1.73m² need dose adjustment; patients on hemodialysis require supplemental doses after each session.
Side Effects
Common Side Effects
- Somnolence/drowsiness — Most common; affects 19–21% of patients in clinical trials
- Dizziness — Affects 17–28% of patients; risk of falls, especially in elderly
- Ataxia (unsteady gait) — Affects 12–13%; significant fall risk
- Fatigue — Affects 11%
- Peripheral edema — Swelling in hands and feet; affects 8%
- Weight gain — Modest but common with long-term use
- Cognitive effects — Memory problems, difficulty concentrating ("brain fog")
- Blurred or double vision — Affects 6%
Serious Side Effects
- Respiratory depression — FDA added a boxed warning in 2 019 for serious respiratory depression when combined with CNS depressants (opioids, benzodiazepines, alcohol). Risk is highest in elderly, those with COPD, and those on multiple CNS depressants.
- Suicidal ideation — FDA class warning for all antiepileptic drugs; monitor for mood changes
- Anaphylaxis and angioedema — Rare but serious hypersensitivity reactions
The Abuse and Dependence Problem
Gabapentin was initially considered to have no abuse potential, which is why it was not scheduled as a controlled substance federally. However, evidence has accumulated that gabapentin has significant abuse potential, particularly in patients with a history of opioid use disorder. Gabapentin produces euphoria, relaxation, and potentiates opioid effects — making it attractive to people who misuse drugs.
Several states (Kentucky, Tennessee, Michigan, Virginia, and others) have classified gabapentin as a Schedule V controlled substance. The FDA has been petitioned to schedule gabapentin federally. Prescribers should exercise caution in patients with substance use disorder history and monitor for signs of misuse.
Drug Interactions
- Opioids — Significantly increased risk of respiratory depression and death; FDA boxed warning
- Benzodiazepines — Additive CNS depression; increased respiratory depression risk
- Alcohol — Additive CNS depression; avoid
- Antacids (aluminum/magnesium) — Reduce gabapentin absorption by up to 20%; separate by ≥2 hours
- Morphine — Morphine increases gabapentin AUC by 44%; monitor for increased gabapentin toxicity
How to Stop Gabapentin Safely
Gabapentin should not be stopped abruptly. Sudden discontinuation can cause withdrawal symptoms including anxiety, insomnia, nausea, sweating, and — in rare cases — seizures (even in patients taking it for non-epilepsy indications). Gabapentin should be tapered gradually over at least 1 week (longer for higher doses or prolonged use). See our article on stopping gabapentin for a detailed tapering guide.
References
- Wiffen PJ, et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;6:CD007938.
- FDA Drug Safety Communication: FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR). 2019.
- Smith RV, et al. Gabapentin misuse, abuse and diversion: a systematic review. Addiction. 2016;111(7):1160-1174.
Save up to 80% on this medication
Use a free RxGo discount card at 67,000+ pharmacies — no sign-up, no insurance needed.
About the Author
James Okafor, RPh, MBA
Registered Pharmacist & Health Economics Writer
James Okafor is a registered pharmacist with over 12 years of experience in retail and clinical pharmacy settings. He holds an MBA with a focus on healthcare management and specializes in translating complex drug pricing, formulary, and insurance coverage topics into clear, actionable guidance for patients. Before joining RxGuide, James worked as a clinical pharmacist at a regional hospital system and as a pharmacy benefits consultant for a national PBM. His writing focuses on cost transparency, generic alternatives, and helping patients navigate the U.S. prescription drug system.
View full profile on our Editorial Team page →Get the RxGo app — free prescription discounts on the go
Works at 67,000+ pharmacies · No membership needed